Navigation Links
Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today
Date:10/18/2010

THOUSAND OAKS, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will review the results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy) and will discuss how these results inform the appropriate use of erythropoiesis-stimulating agents (ESAs) for chronic renal failure (CRF) patients at today's meeting of the Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC).

"This advisory committee meeting is a valuable forum for the FDA, Amgen and the nephrology community to review the results from TREAT, which further inform use of ESAs in patients with chronic renal failure who are not on dialysis," said Reshma Kewalramani, M.D., FASN, executive director, Global Development at Amgen. "We look forward to sharing our analyses of TREAT and describing proposed label changes that will help guide nephrologists in focusing their use of ESA therapy on patients most likely to benefit."

TREAT, the largest study of ESA use in CRF patients to date, is a randomized, double-blind, placebo-controlled, Phase 3 study of patients with moderate kidney dysfunction who were not on dialysis, had moderate anemia and type-2 diabetes and were treated to a hemoglobin target of 13 g/dL, a higher level than recommended in the current approved ESA label. The study did not meet its endpoints of demonstrating a reduction in all-cause mortality, cardiovascular morbidity or end-stage renal disease and showed an increased risk of stroke in the Aranesp (darbepoetin alfa) arm, among other key findings.

The results from TREAT provide important information about the cardiovascular risks of treating CRF patients with ESAs to a hemoglobin target of 13 g/dL or greater. Cardiovascular risks have been reflected in the boxed warning of the FDA-approved ESA labels since 2007 and, in December 2009, Amgen further strengthened the
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... WOONSOCKET, R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Worldwide, Inc. (NYSE: OWW ) will host a conference call to discuss the ... Wednesday, May 5, 2010 at 10:00 a.m. EDT ( 9:00 a.m. CDT ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20070813/AQM125LOGO ) , ... A live webcast of the call can be accessed through the Orbitz Worldwide Investor Relations ...
... Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), a biopharmaceutical company ... Paul F. Truex , Anthera,s President and Chief Executive Officer will present ... MA on Monday, May 3, 2010 at approximately ... , , ...
Cached Medicine Technology:Orbitz Worldwide, Inc. to Host First Quarter 2010 Earnings Call on May 5 2Orbitz Worldwide, Inc. to Host First Quarter 2010 Earnings Call on May 5 3Anthera Pharmaceuticals to Present at Deutsche Bank Securities' 35th Annual Health Care Conference 2
(Date:4/23/2014)... As evidence mounts showing the potential health benefits of ... people are taking supplements. And the chemical industry is ... supplements, health effects could deter growth, so the industry ... claims, according to the cover story in Chemical ... of the American Chemical Society. , Melody M. Bomgardner, ...
(Date:4/23/2014)... R.I. Parents and physicians concerned about an increase ... marijuana can breathe a sigh of relief. According to ... 20 years worth of data from states with and ... lead to increased use among adolescents. The study is ... Journal of Adolescent Health . , "Any time ...
(Date:4/23/2014)... has been a rapidly evolving pursuit with many ... in the research road, scientists have found a ... with the disease. The report, which appears in ... have important implications for developing novel treatments. , ... that for years, research has suggested a link ...
(Date:4/22/2014)... for low-income patients may ease the financial burden ... patient health, researchers have concluded. , A study ... avoid costs associated with insurance administration can help ... and emergency room visits, according to Mark Agee, ... The researchers estimated that the major hospital in ...
(Date:4/22/2014)... The International Communication Association will hold its ... The theme of the 2014 conference will explore ... and digital society. , Featuring over 2,300 academic ... Communication scholars representing over 40 countries, the ICA ... in the world. This year,s conference features sessions ...
Breaking Medicine News(10 mins):Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
... be GI Awards, Honored for Commitment to Patient ... ... Procter and Gamble,Pharmaceuticals (P&G) is encouraging GI and Endoscopy professionals to,recognize outstanding ... support of the Society of Gastroenterology,Nurses and Associates, Inc. (SGNA) GI Nurses ...
... The apples and apple juice you consume may have ... in the body in the colon. New ... apple juice components actually enhance biological mechanisms that produce ... Using human fecal matter as the test substance, German ...
... MD: Artemisinins in Malaria Therapy, written by WRAIR researchers Dr. ... J. Weina (Division of Experimental Therapeutics at the WRAIR, Silver ... and recent developments in the treatment of one of the ... mankind malaria. , WRAIR, initially known as the Army ...
... Vitamin Stix Drink Mix, BROOKLYN, N.Y., March 26 ... your vitamins, 4C Totally Light2Go(TM) Vitamin Stix!,Packed with vitamins ... quickly becoming a staple for the gal on the ... three flavors of the 4C,Totally Light2Go(TM) Vitamin Stix have ...
... Increase of 126% ... -, - Removal of the Going Concern Qualification by its Independent ... Public Accountants - ... March 26 XELR8 Holdings, Inc. (Amex:,BZI), a provider of functional foods, beverages and nutritional,supplements, today ...
... SHANGHAI, China, March 26 /Xinhua-PRNewswire-FirstCall/ -- ... a leading developer,manufacturer and distributor of ... that its wholly owned subsidiary Shanghai ... an agreement with Shanghai,Disinfection Association (SDA), ...
Cached Medicine News:Health News:Nationwide Awards Recognize Nurses, Associates and Nursing Teams That Specialize in Gastroenterology and Endoscopy 2Health News:Nationwide Awards Recognize Nurses, Associates and Nursing Teams That Specialize in Gastroenterology and Endoscopy 3Health News:WRAIR investigators pioneering work on an exciting new class of antimalarial compounds 2Health News:Flavor and Vitamins on the Go 2Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 2Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 3Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 4Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 5Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 6Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 7Health News:XELR8 Holdings Announces Fiscal 2007 Financial Results 8Health News:Shanghai Disinfection Association and Linkwell Corporation Co-Establish the 'Shanghai Disinfection Association Laboratory Center' 2Health News:Shanghai Disinfection Association and Linkwell Corporation Co-Establish the 'Shanghai Disinfection Association Laboratory Center' 3
MedLook 3.0 is a medical billing software....
Managed care is a billing and tracking system....
... billing program dealing with the clerical aspects ... standard Health Insurance Claim Form, or CMS-1500. ... the internet. This means that you can ... home or work without using a web ...
... is a medical practice management ... tools and interfaces. This medical ... scheduling, patient demographics, insurance company ... paper and electronic claims filing ...
Medicine Products: